Physician profile
Lara E Ballard
NPI 1952628687
$522.76
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1.98 · 2022: $333 · 2023: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $163.57 | 2022-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $119.32 | 2022 | |
| Abbvie INC. | $61.09 | 2022 | |
| Lilly USA, LLC | $55.54 | 2023 | Mounjaro |
| Organon LLC | $36.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2022 | |
| Amgen INC. | $17.76 | 2022 | |
| Coopersurgical, INC. | $17.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.32 | 2022 | |
| Abbott Laboratories | $13.01 | 2022 | |
| Genentech USA, INC. | $1.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.